{"url":"https://newsforagent.com/news/2026-11-18/alvotech-ubs-biopharma-conference-pipeline","markdown_url":"https://newsforagent.com/news/2026-11-18/alvotech-ubs-biopharma-conference-pipeline.md","title":"Alvotech Touts $2 Billion Infrastructure at UBS Conference","headline":"Alvotech Founder Robert Wessman Details $2 Billion Biosimilar Buildout at UBS Conference","description":"Alvotech founder Robert Wessman told the UBS Global Biopharma Conference the biosimilar maker has invested over $2 billion in infrastructure and works.","section":"Business","published_at":"2026-11-18T01:20:01+00:00","modified_at":"2026-11-18T01:20:01+00:00","author":"News Desk","key_takeaways":["Alvotech has invested over $2 billion in infrastructure, founder Robert Wessman said at the UBS Global Biopharma Conference in London.","Alvotech has built a commercial network with 20 partners, including Teva in the U.S. and Advanz and STADA in Europe.","Alvotech reported adjusted revenue of $323.4 million for the nine months to September 30, 2026, down 23% year-over-year."],"companies":[{"name":"Alvotech","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00000ty/alvotech","website":"http://www.alvotech.com"},{"name":"UBS Investment Bank","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0007vpr/ubs-investment-bank","website":"https://www.ubs.com/global/en/investment-bank.html"}],"source":{"publisher":"Seeking Alpha","title":"Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript","url":"https://seekingalpha.com/article/4969323-alvotech-alvo-presents-at-ubs-global-biopharma-conference-2026-transcript?source=feed_all_articles"},"other_sources":[],"tags":["Business","Alvotech","UBS Investment Bank"],"body_markdown":"Alvotech has invested more than $2 billion in infrastructure and built a commercial network of 20 partners, founder and executive chairman Robert Wessman said at the UBS Global Biopharma Conference in London on November 17, 2026. Wessman described the company's pipeline as one of the largest in biosimilar development, according to a transcript published by [Seeking Alpha](https://seekingalpha.com/article/4969323-alvotech-alvo-presents-at-ubs-global-biopharma-conference-2026-transcript?source=feed_all_articles).\n\n## Wessman's Case for Alvotech's Pipeline\n\n[Alvotech](https://akta.pro/company-profiles/00000ty/alvotech) is a Reykjavík-based biotechnology company founded in 2013 that develops and manufactures biosimilar monoclonal antibodies for immunology, ophthalmology, oncology and bone health. Wessman told the conference the company was built around end-to-end research and manufacturing, from drug substance and sterile fill-finish to assembly of its autoinjector.\n\n\"We have built out the commercial network now with 20 different partners, including Teva in U.S. and Advanz and STADA in Europe,\" Wessman said. He added that Alvotech has \"one of the largest pipeline in hub developed pipeline.\"\n\nThe session was hosted by Ashwani Verma of [UBS Investment Bank](https://akta.pro/company-profiles/0007vpr/ubs-investment-bank)'s research division, who covers small and mid-cap biotech and specialty pharma. Chief strategy officer Balaji Prasad also represented Alvotech at the conference.\n\n## Alvotech's Funding and Partner Records\n\nAlvotech closed a $165 million capital raise in June 2026 through an underwritten public offering of $98 million and a concurrent private placement of $67 million at $3.75 per share, according to akta.pro [company records](https://akta.pro/company-data). The company said the proceeds would fund biosimilar development, commercialization and potential debt refinancing.\n\nThe same records list Teva Pharmaceutical Industries as Alvotech's strategic commercialization partner for multiple biosimilars, covering U.S. commercialization and select global markets. Advanz Pharma is listed as the European commercialization partner for Gobivaz, a golimumab biosimilar, and additional Alvotech biosimilars.\n\n## Alvotech's Run-Up to the Conference\n\nAlvotech reported adjusted revenue of $323.4 million for the nine months to September 30, 2026, down 23% year-over-year, with adjusted EBITDA of $78.3 million, Stock Titan reported on November 11, 2026. In October 2026, the company announced FDA approval of a new manufacturing process for its biosimilar SIMLANDI that more than doubles drug substance output per batch, Stock Titan reported. Alvotech and Advanz Pharma also filed an EMA application in October 2026 for an 8 mg strength biosimilar to Eylea (aflibercept), the first such application worldwide, according to GlobeNewswire.\n\n## Alvotech's Eylea Launch Window\n\nAlvotech's settlement and license agreement with Regeneron enables a U.S. launch of its AVT06 Eylea biosimilar in the fourth quarter of 2026, contingent on FDA approval, according to company records.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}